ProfileGDS5678 / 1432663_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 4% 4% 4% 4% 4% 4% 4% 12% 4% 4% 4% 4% 4% 4% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.029324
GSM967853U87-EV human glioblastoma xenograft - Control 22.008654
GSM967854U87-EV human glioblastoma xenograft - Control 32.010954
GSM967855U87-EV human glioblastoma xenograft - Control 41.964784
GSM967856U87-EV human glioblastoma xenograft - Control 51.953344
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.05394
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.027054
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.2902112
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 41.990114
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.004434
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 21.992164
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 31.991414
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.000834
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.000574